|
Bad news out today from Infinity Pharmaceuticals. The Cambridge, MA-based biotech company said it is halting a mid-stage clinical trial of its drug for pancreatic cancer early after learning that patients were living longer in the placebo comparison group. Infinity (NASDAQ: INFI... Read more »
Rising stars in the local startup community BarkBox, HackNY, and Gotham Greens will be on hand at Xconomy Forum: New York’s Venture Emergence event on Feb. 1. They will enlighten the crowd with “burst” presentations, during which they’ll describe their companies... Read more »
It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital. Today he’ll make a similar presentation to the New Jersey... Read more »
It’s a question as old as human nature. You’ve heard the stories, you know all the famous examples. Steve Jobs, Larry Ellison, Michael Eisner, the list goes on. All difficult characters with strong personalities—and hugely successful companies.
So, in today’s ultra-competitive tech... Read more »
Prostate cancer was once a backwater for innovation, but suddenly it’s become one of the most competitive battlegrounds in all of biotech. And one of the darkhorses in this race, Bothell, WA and Vancouver, BC-based OncoGenex Pharmaceuticals, is getting ready to show... Read more »
Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French.
The concept was unorthodox 25 years ago,... Read more »
It was a busy news week in the New England life sciences scene, with acquisitions, clinical data, and partnership deals.
—Thanks to a new co-promotion deal, Genzyme will begin marketing a diagnostic test for thyroid cancer developed by South San Francisco-based Veracyte. Genzyme,... Read more »
Chair of Dept. of Genetics and Development, Columbia University
CEO, Renaissance Venture Capital Fund
Managing Director, Versant Ventures
CEO, CyPhy Works
Assoc. Prof., Dept. of Cell Biology, Scripps Research Institute
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
